钇 -90 微球选择性内放射治疗的研究现状与进展
摘要
脏恶性肿瘤，也可作为接受肝移植术、肝切除术等治疗前的新辅助治疗。在本综述中，我们总结了钇 -90 微球选择性内放
射治疗肝细胞癌、胆管细胞癌及转移性肝癌等肝脏恶性肿瘤的最新进展。钇 -90 微球选择性内放射治疗包括：钇 -90 玻璃
微球放射治疗和钇 -90 树脂微球放射治疗。据报道，两者的抗肿瘤作用相似 ; 然而，与钇 -90 玻璃微球放射治疗相比，钇 -90
树脂微球放射治疗具有生物相容性更好，在人体组织内无毒无害。副作用相对更小，发生不良事件的风险更低，患者痛苦少，
生活质量较高，术后留院观察时间短等优势。如果手术根治性治疗不可行，钇 -90 微球选择性内放射治疗可用于早期原发
性肝癌，或作为肝移植前的新辅助治疗。对于门静脉血栓形成有限且肝功能保留的特定患者，也可以考虑使用钇 -90 微球
选择性内放射治疗。关于钇 -90 微球选择性内放射治疗与其他治疗方式（如局部消融、化学栓塞或全身治疗）联合治疗的
研究已经积极进行，并且仍在进行中。
关键词
全文:
PDF参考
[1] Rumgay H,Arnold M,Ferlay J,et al. Global burden
of primary liver cancer in 2020 and predictions to 2040[J]. J
Hepatol,2022,77(6):1598-1606.
[2] Sung H,Ferlay J,Siegel RL,et al.Global Cancer
Statistics 2020:GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries[J].CA Cancer J
Clin,2021,71(3):209249.DOI:10.1158/1538-7445.sabcs23-
po4-14-11.
[3] 竺瑾怡，吴文泽 . 大肝癌微波消融联合靶免疫治疗
的研究进展 [J]. 医学理论与实践，2023,36(5):749-752.
[4] Faiella E,Calabrese A,Santucci D,et al. Combined
trans-arterial embolization and ablation for the treatment of
large(>3 cm)liver metastases:review of the literature[J]. Clin
Med,2022,11(19):5576.
[5]Lewandowski RJ, Geschwind JF, Liapi E, Salem
R. Transcatheter intraarterial therapies: rationale and
overview. Radiology. 2011;259(3):641-657. doi:10.1148/
radiol.11081489
[6]Lau W Y, Teoh Y L, Win K M, et al. Current role of
selective internal radiation with yttrium-90 in liver tumors [J].
Future Oncol, 2016, 12 (8): 2174.
[7]Carr BI. Hepatic arterial 90Yttrium glass microspheres
(Therasphere) for unresectable hepatocellular carcinoma: interim
safety and survival data on 65 patients. Liver Transpl. 2004;10(2
Suppl 1):S107-S110. doi:10.1002/lt.20036.
[8] 陈钰桐 .125I 粒子组织间植入治疗结直肠癌肝转移安
全性及有效性的相关研究 [D]. 东南大学 ,2022.DOI:10.27014/
d.cnki.gdnau.2022.000639.
[9] 申 超 波 . 核 技 术 应 用 走 进 新 时 代 [J]. 国 防 科 技 工
业 ,2022,(10):28-33.
[10]Vogel A, Martinelli E; ESMO Guidelines Committee.
Electronic address: clinicalguidelines@esmo.org; ESMO
Guidelines Committee. Updated treatment recommendations for
hepatocellular carcinoma (HCC) from the ESMO Clinical Practice
Guidelines. Ann Oncol. 2021;32(6):801-805. doi:10.1016/
j.annonc.2021.02.014.
[11] 原发性肝癌诊疗指南（2024 年版）[J]. 肿瘤综合治
疗电子杂志 ,2024,10(03):17-68.
[12]Vilgrain V, Pereira H, Assenat E, et al. Efficacy and
safety of selective internal radiotherapy with yttrium-90 resin
microspheres compared with sorafenib in locally advanced
and inoperable hepatocellular carcinoma (SARAH): an open-
label randomised controlled phase 3 trial. Lancet Oncol.
2017;18(12):1624-1636. doi:10.1016/S1470-2045(17)30683-6.
[13]Hermann AL, Dieudonné A, Ronot M, et al.
Relationship of Tumor Radiation-absorbed Dose to Survival and
Response in Hepatocellular Carcinoma Treated with Transarterial
Radioembolization with 90Y in the SARAH Study. Radiology.
2020;296(3):673-684. doi:10.1148/radiol.2020191606.
[14]Garin E, Tselikas L, Guiu B, et al. Personalised versus
standard dosimetry approach of selective internal radiation
therapy in patients with locally advanced hepatocellular carcinoma
(DOSISPHERE-01): a randomised, multicentre, open-label
phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17-29.
doi:10.1016/S2468-1253(20)30290-9.
[15]Dhondt E, Lambert B, Hermie L, et al. 9 0Y
Radioembolization versus Drug-eluting Bead Chemoembolization
for Unresectable Hepatocellular Carcinoma: Results from the
TRACE Phase II Randomized Controlled Trial. Radiology.
2022;303(3):699-710. doi:10.1148/radiol.211806.
[16]Villalobos A, Arndt L, Cheng B, et al. Yttrium-90
Radiation Segmentectomy of Hepatocellular Carcinoma: A
Comparative Study of the Effectiveness, Safety, and Dosimetry of
Glass-Based versus Resin-Based Microspheres. J Vasc Interv
Radiol. 2023;34(7):1226-1234. doi:10.1016/j.jvir.2023.02.030.
[17]Laidlaw GL, Johnson GE. Recognizing and Managing
Adverse Events in Y-90 Radioembolization. Semin Intervent
Radiol. 2021;38(4):453-459. doi:10.1055/s-0041-1735617.
[18]Henriksson R, Bergström P, Franzén L, Lewin F,
Wagenius G. Aspects on reducing gastrointestinal adverse effects
associated with radiotherapy. Acta Oncol. 1999;38(02):159–164.
doi: 10.1080/028418699431564.
[19]Kallini J R, Gabr A, Thorlund K. Comparison of the
adverse event profile of TheraSphere ® with SIR-Spheres ® for the
treatment of unresectable hepatocellular carcinoma: a systematic
review . Cardiovasc Intervent Radiol. 2017;40(07):1033–1043.
doi: 10.1007/s00270-017-1594-4.
[20]Lee YB, Nam JY, Cho EJ, et al. A Phase I/IIa
Trial of Yttrium-90 Radioembolization in Combination with
Durvalumab for Locally Advanced Unresectable Hepatocellular
Carcinoma. Clin Cancer Res. 2023;29(18):3650-3658.
doi:10.1158/1078-0432.CCR-23-0581.
[21]SALEM R,JOHNSON G E,KIM E,et al.Yttrium-
90radioembolization for the treatment of solitary,unresectable
HCC:the LEGACY study[J].Hepatology,2021,74(5):2342-2352.
[22]ALISEDA D,MARTÍ-CRUCHAGA P,ZOZAYA
G,et al.Liver resection and transplantation following yttrium-
90radioembolization for primary malignant liver tumors:a 15-year
single-center experience[J].Cancers (Basel),2023,15(3):733.
[23]Abouchaleh N, Gabr A, Ali R, et al. 9 0Y
Radioembolization for Locally Advanced Hepatocellular
Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes
in a 185-Patient Cohort. J Nucl Med. 2018;59(7):1042-1048.
doi:10.2967/jnumed.117.199752.
[24]Kulik LM,Carr Bi,Mulcahy MF,et al.Safety and efficacy
of 90Yradiotherapy for hepatocellular carcinoma with and
withoutportal vein thrombosis[J].Hepatology,2008,47(1):71-81.
[25]Kim E, Sher A, Abboud G, et al. Radiation
segmentectomy for curative intent of unresectable very early to
early stage hepatocellular carcinoma (RASER): a single-centre,
single-arm study. Lancet Gastroenterol Hepatol. 2022;7(9):843-
850. doi:10.1016/S2468-1253(22)00091-7.
[26]Ponziani FR, Santopaolo F, Posa A, et al. SIRT in
2025. Cardiovasc Intervent Radiol. 2022;45(11):1622-1633.
doi:10.1007/s00270-022-03228-6.
[27]Chan SL, Chotipanich C, Choo SP, et al. Selective
Internal Radiation Therapy with Yttrium-90 Resin Microspheres
Followed by Gemcitabine plus Cisplatin for Unresectable
Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm
Multicenter Clinical Trial. Liver Cancer. 2022;11(5):451-459.
Published 2022 Jun 15. doi:10.1159/000525489.
[28]Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization
Plus Chemotherapy for First-line Treatment of Locally Advanced
Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA
Oncol. 2020;6(1):51-59. doi:10.1001/jamaoncol.2019.3702.
[29]Barabasch A, Heinzel A, Bruners P, Kraemer NA, Kuhl
CK. Diffusion-weighted MRI Is Superior to PET/CT in Predicting
Survival of Patients Undergoing 90Y Radioembolization of Hepatic
Metastases. Radiology. 2018;288(3):764-773. doi:10.1148/
radiol.2018170408.
[30]Wasan HS, Gibbs P, Sharma NK, et al. First-line
selective internal radiotherapy plus chemotherapy versus
chemotherapy alone in patients with liver metastases from
colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global):
a combined analysis of three multicentre, randomised, phase 3
trials. Lancet Oncol. 2017;18(9):1159-1171. doi:10.1016/S1470-
2045(17)30457-6.
[ 3 1 ] M u l c a h y M F , M a h v a s h A , P r a c h t M , e t a l .
Radioembolization With Chemotherapy for Colorectal Liver
Metastases: A Randomized, Open-Label, International,
Multicenter, Phase III Trial. J Clin Oncol. 2021;39(35):3897-
3907. doi:10.1200/JCO.21.01839.
[32]Alsultan AA, van Roekel C, Barentsz MW, et al.
Dose-Response and Dose-Toxicity Relationships for Glass 90Y
Radioembolization in Patients with Liver Metastases from
Colorectal Cancer. J Nucl Med. 2021;62(11):1616-1623.
doi:10.2967/jnumed.120.255745.
[33]Cholapranee A, van Houten D, Deitrick G, et al. Risk of
liver abscess formation in patients with prior biliary intervention
following yttrium-90 radioembolization. Cardiovasc Intervent
Radiol. 2015;38(2):397-400. doi:10.1007/s00270-014-0947-5.
[34] Ebbers SC, van Roekel C, Braat MNGJA, Barentsz
MW, Lam MGEH, Braat AJAT. Dose-response relationship after
yttrium-90-radioembolization with glass microspheres in patients
with neuroendocrine tumor liver metastases. Eur J Nucl Med Mol
Imaging. 2022;49(5):1700-1710. doi:10.1007/s00259-021-
05642-3.
(8 摘要 Views, 5 PDF Downloads)
Refbacks
- 当前没有refback。